New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Learn More

RBC Capital Maintains a Hold Rating on Gilead Sciences (GILD)

By Noor Ul Ain Rehman | October 03, 2025, 6:28 AM

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best medical stocks to buy now. RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences, Inc. (NASDAQ:GILD) on September 29 and set a price target of $98.00.

Why Gilead Sciences (GILD) Deserves Attention in the Cheap Quarterly Dividend Stocks Category

Gilead Sciences, Inc. (NASDAQ:GILD) reported a 2% growth in its total revenues for fiscal Q2 2025 to $7.1 billion compared to the same period last year, with management attributing the growth to higher HIV, Livdelzi, and Trodelvy sales.

Diluted EPS for the quarter reached $1.56 compared to $1.29 in the prior year period, with the increase primarily driven by net unrealized gains on securities compared to net unrealized losses in 2024 and higher product sales.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biotech company that advances medicines to prevent and treat serious diseases such as cancer, immunodeficiency virus (HIV), viral hepatitis, and COVID-19.

Its portfolio of drugs focuses on medical areas with unmet needs and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others. Gilead Sciences, Inc. (NASDAQ:GILD) operates in over 35 countries.

While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.

Mentioned In This Article

Latest News